Consequently, several pan-PI3K and dual PI3K/mTOR inhibitors, in particular BKM120 and BEZ235, are undergoing phase I clinical development to assess safety, dose, and preliminary efficacy in patients with advanced leukemias, relapsed or refractory acute lymphoblastic and myelocytic leukemia (see text footnote 2). Here, PIK3CA is linked to leukemia.